Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

240.27
+0.50000.21%
Volume:60.69K
Turnover:14.52M
Market Cap:15.90B
PE:18.54
High:242.52
Open:239.70
Low:237.23
Close:239.77
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.94
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:9.60
PE(LYR):-54.39

Loading ...

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
·
Aug 31

Movement Alert|Ascendis Pharma A/S Rises 5.92% in Regular Trading, Global Patent Settlement Reached with BioMarin Over Yuviwel

Market Focus
·
Aug 31

Ascendis Pharma price target lowered to $330 from $333 at Jefferies

TIPRANKS
·
Aug 31

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Aug 31

Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)

THOMSON REUTERS
·
Aug 31

Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Aug 31

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Aug 31

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Aug 31

HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target

MT Newswires Live
·
Aug 27

Ascendis Pharma initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Aug 27

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026

Reuters
·
Aug 26

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026

THOMSON REUTERS
·
Aug 26

Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside

Simply Wall St.
·
Aug 25

Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares

Reuters
·
Aug 19

Eyconis Announces Initiation of First-in-Human Clinical Trial of Eyc-0305 in Treatment-NaÏVe Wet Age-Related Macular Degeneration Patients

THOMSON REUTERS
·
Aug 18

Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall St.
·
Aug 16

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

MT Newswires Live
·
Aug 14

Ascendis Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Aug 14